A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

Open to people ages 18-99

• Subject must have a diagnosis of CLL that meets 2008 Modified International Workshop on Chronic Lymphocytic Leukemia National Cancer Institute-Working Group (iwCLL NCI-WG) criteria
• Subject has relapsed/refractory disease with an indication for treatment
• Subject has refractory disease or developed recurrence after therapy with a BCR PI
• Subject must have an Eastern Cooperative Oncology Group performance score of equal to or less than 2
• Subject must have adequate bone marrow function at Screening
• Subject must have adequate coagulation profile, renal, and hepatic function, per laboratory reference range at Screening

• Subject has undergone an allogeneic stem cell transplant within the past year
• Subject has developed Richter's transformation confirmed by biopsy
• Subject has active and uncontrolled autoimmune cytopenia
• Subject has malabsorption syndrome or other condition that precludes enteral route of administration
• Subject is human immunodeficiency virus (HIV) positive or has chronic hepatitis B or hepatitis C virus requiring treatment
• Subject has known contraindication or allergy to both xanthine oxidase inhibitors and rasburicase.